LAB:NASDAQStandard BioTools Inc. analysis
Data as of Jun 15, 2026 - not real-time
- Latest price
- $0.85
- Risk: high
- 8/10High risk
Summary
Standard BioTools is trading well below its book value and carries a substantial cash cushion, but it is wrestling with negative operating cash flow and widening losses. Technical indicators show a neutral price trend, a bearish MACD crossover and an RSI that suggests the stock is edging into oversold territory, while volume is picking up. The company is poised to merge with Treeline Biosciences, a development that could unlock a deeper pipeline of therapeutics and potentially improve earnings prospects. However, the merger also introduces execution risk and uncertainty around valuation.
Given the current pricing, strong balance sheet, and the strategic merger, the upside potential is notable, yet the combination of high volatility, elevated beta, and ongoing profitability challenges warrants a cautious stance.
Given the current pricing, strong balance sheet, and the strategic merger, the upside potential is notable, yet the combination of high volatility, elevated beta, and ongoing profitability challenges warrants a cautious stance.
Market outlook
Short term
< 1 yearNeutral
Model confidence6/106 out of 10
Key factors
- bearish MACD signal
- oversold RSI level
- merger uncertainty
Medium term
1–3 yearsPositive
Model confidence7/107 out of 10
Key factors
- potential revenue uplift from combined pipeline
- strong cash position relative to debt
- valuation gap to book value
Long term
> 3 yearsPositive
Model confidence8/108 out of 10
Key factors
- strategic synergies post‑merger
- long‑term growth in proteomics and genomics markets
- improved earnings visibility as integration matures
Key metrics
Financial health
Revenue Growth4.60%
Profit Margin90.67%
P/E Ratio-85.0
ROE-9.86%
ROA-8.05%
Debt/Equity5.26
P/B Ratio0.6
Op. Cash Flow$-90657000
Free Cash Flow$-13438500
Industry P/E24.7
Technical analysis
TrendNeutral
RSI39.3
Support$0.79
Resistance$1.29
MA 20$1.03
MA 50$0.98
MA 200$1.20
MACDBearish
VolumeIncreasing
Fear & Greed Index92.88
Valuation
Target Price$1.55
Upside/Downside82.37%
GradeUndervalued
TypeValue
Risk assessment
Beta1.67
Volatility127.43%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.